JP7466466B2 - 癌の診断および治療のための組成物および方法 - Google Patents

癌の診断および治療のための組成物および方法 Download PDF

Info

Publication number
JP7466466B2
JP7466466B2 JP2020568252A JP2020568252A JP7466466B2 JP 7466466 B2 JP7466466 B2 JP 7466466B2 JP 2020568252 A JP2020568252 A JP 2020568252A JP 2020568252 A JP2020568252 A JP 2020568252A JP 7466466 B2 JP7466466 B2 JP 7466466B2
Authority
JP
Japan
Prior art keywords
edb
binding
cancer
fibronectin extra
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020568252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526808A (ja
JP2021526808A5 (https=
Inventor
ウグル サヒン，
ボニー ギャビー ルイ，
ナジャ サロモン，
ジョイスリン ヴューステヒューブ－ローシュ，
マティン ダネシュダール，
ハンス－ウルリッヒ シュモルト，
マルクス フィードラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of JP2021526808A publication Critical patent/JP2021526808A/ja
Publication of JP2021526808A5 publication Critical patent/JP2021526808A5/ja
Application granted granted Critical
Publication of JP7466466B2 publication Critical patent/JP7466466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
JP2020568252A 2018-06-08 2019-06-06 癌の診断および治療のための組成物および方法 Active JP7466466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2018/065205 2018-06-08
PCT/EP2018/065205 WO2019233605A1 (en) 2018-06-08 2018-06-08 Compositions and methods for diagnosis and treatment of cancer
PCT/EP2019/064872 WO2019234190A1 (en) 2018-06-08 2019-06-06 Compositions and methods for diagnosis and treatment of cancer

Publications (3)

Publication Number Publication Date
JP2021526808A JP2021526808A (ja) 2021-10-11
JP2021526808A5 JP2021526808A5 (https=) 2023-04-17
JP7466466B2 true JP7466466B2 (ja) 2024-04-12

Family

ID=62636178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020568252A Active JP7466466B2 (ja) 2018-06-08 2019-06-06 癌の診断および治療のための組成物および方法

Country Status (10)

Country Link
US (2) US11673939B2 (https=)
EP (1) EP3802585A1 (https=)
JP (1) JP7466466B2 (https=)
KR (2) KR20240142617A (https=)
CN (2) CN112424220A (https=)
AU (1) AU2019282316B2 (https=)
BR (1) BR112020024034A2 (https=)
CA (1) CA3101246A1 (https=)
MX (1) MX2020013205A (https=)
WO (2) WO2019233605A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
KR102649794B1 (ko) * 2020-10-19 2024-03-22 고려대학교 산학협력단 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500875A (ja) 2006-08-21 2010-01-14 アイトゲネシシェ・テヒニーシェ・ホッホシューレ・チューリッヒ Ｆｙｎキナーゼの改変ｓｈ３ドメインを含む特異的かつ高親和性の結合タンパク質
JP2012505929A (ja) 2008-10-20 2012-03-08 グワンジュ・インスティテュート・オブ・サイエンス・アンド・テクノロジー 二座ペプチドバインダー
WO2016022597A1 (en) 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use
WO2016146639A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
WO2017049009A1 (en) 2015-09-15 2017-03-23 Genentech, Inc. Cystine knot scaffold platform

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111302A1 (en) 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
WO2007004060A2 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
CA2822938A1 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
AU2014252354A1 (en) * 2013-04-11 2015-11-19 Merck Patent Gmbh Potent inhibitors of human matriptase derived from McotI-II variants
US20170218040A1 (en) * 2016-02-02 2017-08-03 Julio A. Camarero Palao Proteolically resistant cyclotides with angiotensin 1-7 like activity
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500875A (ja) 2006-08-21 2010-01-14 アイトゲネシシェ・テヒニーシェ・ホッホシューレ・チューリッヒ Ｆｙｎキナーゼの改変ｓｈ３ドメインを含む特異的かつ高親和性の結合タンパク質
JP2012505929A (ja) 2008-10-20 2012-03-08 グワンジュ・インスティテュート・オブ・サイエンス・アンド・テクノロジー 二座ペプチドバインダー
WO2016022597A1 (en) 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use
WO2016146639A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
WO2017049009A1 (en) 2015-09-15 2017-03-23 Genentech, Inc. Cystine knot scaffold platform

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GEBAUER, Michaela et al.，Combinatorial Design of an Anticalin Directed against the Extra-Domain B for the Specific Targeting of Oncofetal Fibronectin，J. Mol. Biol.，2013年，425，pp. 780-802
MAAB, Franziska et al.，Cystine-knot peptides targeting cancer-relevant human cytotoxic T lymphocyte associated antigen 4 (CTLA-4)，Journal of Peptide Science，2015年05月10日，21，pp. 651-660
PARK, Jinho et al.，Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging，Journal of Controlled Release，2012年09月03日，163，pp. 111-118

Also Published As

Publication number Publication date
JP2021526808A (ja) 2021-10-11
EP3802585A1 (en) 2021-04-14
US20210246191A1 (en) 2021-08-12
CN116987180A (zh) 2023-11-03
WO2019233605A1 (en) 2019-12-12
MX2020013205A (es) 2021-02-26
KR20210020006A (ko) 2021-02-23
BR112020024034A2 (pt) 2021-02-23
CA3101246A1 (en) 2019-12-12
US20240002471A1 (en) 2024-01-04
CN112424220A (zh) 2021-02-26
WO2019234190A1 (en) 2019-12-12
NZ770391A (en) 2024-09-27
KR20240142617A (ko) 2024-09-30
US11673939B2 (en) 2023-06-13
AU2019282316A1 (en) 2020-12-24
US12516104B2 (en) 2026-01-06
AU2019282316B2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
JP6739132B2 (ja) がんの診断及び処置のための組成物及び方法
JP2015193653A (ja) プロタンパク質およびその使用方法
AU2010234459A1 (en) Human protein scaffold with controlled serum pharmacokinetics
US12516104B2 (en) Compositions and methods for diagnosis and treatment of cancer
US20240115717A1 (en) Chlorotoxin derivatives and use thereof
KR20240139054A (ko) 가교 항체
HK1247931B (zh) 用於诊断和治疗癌症的组合物和方法
HK1242717B (en) Compositions and methods for diagnosis and treatment of cancer
HK1242717A1 (en) Compositions and methods for diagnosis and treatment of cancer
NZ734680B2 (en) Compositions and methods for diagnosis and treatment of cancer
BR112017018522B1 (pt) Peptídeo de ligação a seprase; agente de ligação a seprase compreendendo o dito peptídeo de ligação a seprase; ácido nucleico recombinante, o qual codifica o dito peptídeo de ligação a seprase; método para ensaiar a presença e / ou quantidade de seprase numa amostra; método para diagnóstico, detecção e monitoração do câncer em um paciente, composição farmacêutica e uso dos mesmos
JP2025528414A (ja) インテグリンα１０抗体薬物複合体
CN116897161A (zh) 氯毒素衍生物及其用途
Park et al. Mesothelin-binding peptide inhibits cell migration and enables targeted delivery of mitochondrial membrane–damaging peptide to pancreatic tumors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230407

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240402

R150 Certificate of patent or registration of utility model

Ref document number: 7466466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150